Actively Recruiting
Phase IV Study Comparing Metformin Plus SGLT2 Inhibitor and TZD versus Metformin Plus SGLT2 Inhibitor and DPP4 Inhibitor in Adults With Type 2 Diabetes
Led by Boryung Pharmaceutical Co., Ltd · Updated on 2025-09-15
204
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of switching treatment combinations in adults with type 2 diabetes. This phase IV, randomized, open-label, active-controlled, parallel, multicenter study compares the safety and efficacy of changing from Metformin plus SGLT2 inhibitor and DPP4 inhibitor to Metformin plus SGLT2 inhibitor and Thiazolidinedione TZD. This study helps understand how different drug combinations work for managing type 2 diabetes and is sponsored by Boryung Pharmaceutical Co., Ltd. Participants will receive one of two treatments orally once daily for 24 weeks. One group takes Metformin with Dapagliflozin 10 mg and Pioglitazone 30 mg, while the other group takes Metformin with Dapagliflozin 10 mg and Sitagliptin 100 mg. The Metformin dose and schedule remain the same as before screening. Both treatments last for 24 weeks under this study protocol. During the study, researchers will measure changes in HbA1c levels from the start to the end of the 24 weeks to assess blood sugar control. Participants will be monitored regularly to evaluate safety and treatment effects. The total participation time covers the 24-week treatment period, during which participants will have study visits and assessments to track their progress and any side effects.
CONDITIONS
Brief Title
A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes
Research Team
O
Oh
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
